Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?

Area of Science:

• Endocrinology
• Pharmacology
• Immunology

Background:

• Adrenocorticotrophic hormone (ACTH) stimulates adrenal cortex to secrete glucocorticoids (GC) and dehydroepiandrosterone (DHEA).
• GC are catabolic, causing side effects like muscle weakness, bone loss, and increased infection risk.
• DHEA is anabolic and counteracts some GC-induced negative effects, such as diabetes and hypertension.

Purpose of the Study:

• To explore the role of DHEA in mitigating GC side effects.
• To investigate the impact of DHEA deficiency in aging and chronic diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
• To propose DHEA replacement therapy as a strategy to reduce GC-induced damage.

Main Methods:

• Review of existing literature on GC and DHEA physiology and pharmacology.
• Analysis of the impact of GC administration on DHEA levels and associated health outcomes.
• Discussion of the potential benefits of DHEA in specific patient populations.

Main Results:

• DHEA's anabolic properties can counteract GC-induced myopathy, osteopenia, and avascular necrosis.
• Chronic GC use suppresses DHEA production, exacerbating negative effects, particularly in females.
• DHEA deficiency is pronounced in aging and chronic inflammatory/autoimmune diseases.

Conclusions:

• The deleterious effects of chronic GC administration stem from both their catabolic actions and DHEA suppression.
• DHEA replacement therapy holds promise for reducing GC-induced damage, especially in conditions with low DHEA levels.
• Balancing GC and DHEA levels may be crucial for managing chronic diseases and mitigating treatment side effects.